Effect of Recombinant Peptide rLj-RGD4 on the Activity of Murine Melanoma B16 Cells

Abstract: In the present study， we cloned to obtain the rLj-RGD4 peptide， based on the privous work on rLj-RGD3 peptide. We used mouse melanoma as tumor cell model to study whether rLj-RGD4 inhibits B16 cell proliferation，migration， invasion and apoptosis. The results showed that rLj-RGD4 could inhibit the proliferation of B16 cells by MTT assay with an IC50 of 9.6 μmol/L. The results from Transwell method and cell scratch test confirmed that rLj-RGD4 on B16 cell migration and invasion were inhibited in a dose-dependent manner. B16 cells by phalloidin-FITC staining showed that rLj-RGD4 peptide on B16 cytoskeleton damage. The results of Hoechst 33258 and TUNEL-FITC showed that rLj-RGD4 peptide could induce apoptosis of B16 cells; The results showed that the level of cleaved-caspase-8 and cleaved-caspase-3 were significantly increased and the level of Bcl-2 was significantly decreased with the increase of rLj-RGD4 peptide concentration. Thus， rLj-RGD4 peptide has a significant role in promoting apoptosis of B16 cells， with its anti-proliferation and invasion function， may become a candidate of drugs anti-tumor.

CSTR: 32200.14.cjcb.2017.05.0008